Section dedicated to MDS with Ring sideroblasts.
And access to treatment.
The drug Luspatercept was licensed in 2020 by the EMA, and the FDA before that.
Several HTA bodies in the EU have started to assess the cost-efficiency of the drug.
The drug is available in Germany.
In France, there are delays
Portugal will finish their HTA in June 2022
In the UK, the company (BMS) was going to submit to the UK HTA body - NICE - but withdrew their application - and have not scheduled any new dates to review the drug.
BMS has also submitted to the HTA in Canada.
The Canadian HTA body issued an initial recommendation, provided the company agrees to an 85% cost reduction of the drug.
We are awaiting further information, to see whether the pharma company will agree to a price reduction with the canadian government.
Should they do so - there would be no reason why BMS could not agree to a similar scheme in the UK.
Feel free to share thoughts.
MDS with RS and Luspatercept
Moderator: Steering Committee
-
- Posts: 256
- Joined: 20 Nov 2008 14:05
- Contact:
MDS with RS and Luspatercept
Sophie - Patient Liaison
Queries:
Call 0207 733 7558
Email info@mdspatientsupport.org.uk
Please do not send me PM messages on this forum - I do not check it often.
This forum is purely for patient to patient communications. Thanks for your help.
Queries:
Call 0207 733 7558
Email info@mdspatientsupport.org.uk
Please do not send me PM messages on this forum - I do not check it often.
This forum is purely for patient to patient communications. Thanks for your help.
Who is online
Users browsing this forum: No registered users and 2 guests